Med-Fine Capital is a Shanghai-based venture capital firm specializing in early-stage healthcare and life sciences investments across China. The firm focuses on biotech, medical devices, diagnostics, digital health, and healthcare services, managing both RMB and USD funds with a portfolio of over 60 companies.
They made 1 investments in the last 12 months. Average disclosed round size is $39.6M (across 6 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
JZ
Jack Zhou
Founder and Managing Partner
周(
周玉建 (Yujian Zhou)
Managing Partner
YB
Yang Bai
Partner and Managing Director
VD
Vince Deng
Partner and Head of Biotech Investment
AX
An Xiao
Healthcare investment professional
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 VelaVigo | Seed | $60M | Jul 2025 |
| DDegron Therapeutics | Series A | $22M | Jun 2022 |
| LLynk Pharmaceuticals | Unknown | $50M | Aug 2021 |
| LLynk Pharmaceuticals | Series B | $50M | Jan 2021 |
| LLynk Pharmaceuticals | Series A | $20M | Jan 2020 |
| LLynk Pharmaceuticals | Seed | — | Jan 2018 |
| LLarkspur | Unknown | $35.5M | — |
Top Co-Investors
Pivotal Life Sciences4 shared
Legend Capital3 shared
Lilly Asia Ventures2 shared
Next Capital1 shared
Baidu Ventures1 shared
Icon Ventures1 shared
Dyee Capital1 shared
YuanBio Venture Capital1 shared
Panacea Venture1 shared
HighLight Capital1 shared
Shunwei Capital1 shared
Northern Light Venture Capital1 shared
Legend Star1 shared
Decheng Capital1 shared
3E Bioventures Capital1 shared
Polaris Innovation Fund1 shared
Takeda Ventures, Inc.1 shared
Last updated: 8 September 2026